Home | Health News | Themes | Search | Blog | Testimonials | Blood Bank | About Us
 
   
   
   
   
   
   
   
 
testing

 
   
 



Indication & Dosage
 
 
Intravenous
DIABETIC KETOACIDOSIS
Adult: As soluble insulin, given in concentration of 1 unit/ml using an infusion pump: Initially infuse at a rate of 6 units/hr, double or quadruple the rate if blood glucose concentration do not decrease by about 5 mmol/l/hr. If blood glucose concentrations have decreased to 10 mmol/l, reduce the infusion rate to 3 units/hr and continue with 5% glucose to prevent hypoglycaemia, until the patient can eat orally. Do not stop the insulin infusion before SC insulin is started. Ensure adequate fluid replacement and include potassium chloride in the infusion to prevent insulin-induced hypokalaemia.
 
Intravenous
DIABETIC KETOACIDOSIS
Child: As soluble insulin, given in concentration of 1 unit/ml using an infusion pump: Initially infuse at a rate of 0.1 units/kg/hr, double or quadruple the rate if blood glucose concentration do not decrease by about 5 mmol/l/hr. If blood glucose concentrations have decreased to 10 mmol/l, reduce the infusion rate to 0.05 units/kg/hr and continue with 5% glucose to prevent hypoglycaemia, until the patient can eat orally. Do not stop the insulin infusion before SC insulin is started. Ensure adequate fluid replacement and include potassium chloride in the infusion to prevent insulin-induced hypokalaemia.
 
Intramuscular
DIABETIC KETOACIDOSIS
Adult: As soluble insulin, initial loading dose of 20 units, followed by 6 units/hr until blood glucose drops to 10 mmol/l, when the dose is given 2 hrly.
 
Subcutaneous
DIABETES MELLITUS
Adult: Admin according to requirements; inject into thighs, upper arms, buttocks, or abdomen
   
Precautions Pregnancy (insulin requirements tend to fall during the 1st trimester, increase during the 2nd and 3rd) and lactation. Regular monitoring of HbA1c and blood glucose concentrations.
   
Adverse Drug Reactions Hypoglycaemia, insulin resistance, lipoatrophy, hypokalaemia, blurred vision.
   
Interactions Possible absence of hypoglycaemic warning symptoms with β-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermoarelin.
   
   
 

 

SocialTwist Tell-a-Friend
 
 
Home  |   Privacy Policy   |   News Lettter   |   Site Map   |  Disclaimer  |  About Us
   copyright@totalhealthneeds.com   Webmaster:- o3sa.co.in